This Caffeine Version of Tauri-Gum™
is the 7th SKU of this Fast-Growing Product
Line
NEW YORK, NY -- January 14, 2021 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of CBD & CBG
infused Supplement chewing gums (Flavors: Pomegranate, Blood
Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as
an ongoing Pharmaceutical Development initiative, has today
announced that it has completed payment for the entirety of its
initial production run of its caffeine infused version of
Tauri-Gum™. After extensive research, the Company has decided
to infuse each piece chewing gum with 50mg of
caffeine. This product will be manufactured in the
flavor of CHERRY LIME RICKEY and the MSRP, per Blister Pack, is
expected to be set at $9.99 each. The Company expects
that this initial production run will yield approximately 9,000
Blister Packs (900 Retail Display
Boxes). Availability: This caffeine infused
version of Tauri-Gum™ will be available on the Company E-Commerce
website (www.taurigum.com), later this
Quarter.
The Company believes that the completed production run of this
7th SKU of Tauri-Gum™, has the potential to
drive additional revenue growth. In addition to
E-Commerce business, the Company will now have 2 distinct
Tauri-Gum™ SKUs (which contain no Cannabinoids) – to present to
major retailers. Additionally, with air travel being
substantially reduced, a high-quality Caffeine chewing gum may be
of interest to those driving extended distances.
In other news, the Company continues to realize important levels
of progress with respect to a number of different corporate
initiatives. The Company expects to disclose to
shareholders one or more material Agreement(s) / Partnership(s),
within the near term.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) &
(Vitamin C + Zinc “Immune Booster” Flavor: Pear
Bellini). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce website:
www.taurigum.com). Please visit our corporate website, for
additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing
Pharmaceutical Development initiative. This relates to the
development of a proposed Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed for the
following indication: Patients Subjected to Ongoing Chemotherapy
Treatment). On March 18, 2020, the Company announced that it had
filed a provisional U.S. patent application covering its
pharmaceutical grade version of Tauri-Gum™. The Patent, filed
with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS
OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18,
2020 the Company disclosed that it had entered into a Master
Services Agreement with CSTI to lead the Company's clinical
development efforts.
On October 6, 2020, the Company announced that it has been
approved to operate as a U.S. Government Vendor (CAGE CODE #
8QXV4)
The Company is headquartered in Wappingers Falls, New
York. In addition, the Company operates a full time
E-Commerce fulfillment center located in LaGrangeville, New
York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024